37
Participants
Start Date
May 1, 2024
Primary Completion Date
December 31, 2026
Study Completion Date
December 31, 2026
MTBF regimen
"The subjects will be treated with mitoxantrone hydrochloride liposome combined with thiotepa, busulfan and fludarabine as conditioning regimen prior to allo-HSCT.~Mitoxantrone hydrochloride liposome 24mg/m\^2 ivgtt d-7; Ctepide 5mg/kg ivgtt d-6\~-5; Busulfan 0.8mg/kg q6h ivgtt d-4\~-2; Fludarabine 50mg/m\^2 ivgtt d-4\~-2."
First Affiliated Hospital Xi'an Jiaotong University
OTHER